• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Jubilant Therapeutics Appoints Chief Scientific Officer

    Iontas and Fair Journey Biologics Partner with Quell Therapeutics

    Vetter Establishes Office in China

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Vetter Establishes Office in China

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Vetter Establishes Office in China

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Reed-Lane

    Alcami

    Emergent BioSolutions

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Alcami

    Syngene

    Emergent BioSolutions

    Cytovance Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Newsmakers: Peter Soelkner

    A conversation with Peter Soelkner, managing director, Vetter Pharma International GmbH

    Newsmakers: Peter Soelkner
    Related CONTENT
    • Vetter continues its successful performance at the 2021 CMO Leadership Awards
    • Vetter continues to implement its long-term sustainability strategy
    • Vetter Moves Into New HQ
    • Vetter continues its long-term investment strategy to sustain future growth
    • Vetio Animal Health
    Tim Wright, Contract Pharma04.03.17
    Peter Soelkner has been a managing director of Vetter Pharma-Fertigung GmbH & Co. KG since June 2008. In 2009, he was also appointed managing director of Vetter Pharma International GmbH, the company’s marketing and sales organization. At Vetter, from 2003 to 2007, he managed the company’s key account program and global end-to-end supply chain. He left the company for a year to serve as vice president of global key account management at Sartorius Stedim Biotech (USA), before returning to Vetter in 2008.

    Vetter is a global provider for fill and finish of aseptically prefilled syringe systems, cartridges and vials. Headquartered in Ravensburg, Germany, the company operates production facilities in Germany and the U.S., as well as sales offices in Singapore and Tokyo, Japan. The contract development and manufacturing organization (CDMO) serves small, midsize, and the top 10 (bio-)pharmaceutical companies. Its portfolio spans manufacturing from early clinical development through commercial filling and final packaging of parenteral drugs. More than 80% of Vetter’s active projects are biologics, and Vetter currently manufactures five of the world’ top 10. In January, Vetter began operations in its expanded Visual Inspection and Logistics Center in Ravensburg, which cost the company $107 million and took five years to complete. Contract Pharma talked with Mr. Soelkner about trends in the market and Vetter’s response to them.

    —Tim Wright



    Contract Pharma: What pharma/biopharma macro trends are you seeing and how are they trickling down to impact aseptic fill/finish operations?
    Peter Soelkner:
    One trend that we see, in particular, is the increase in the overall complexity of individual drug substances, which, in turn, affects all parties along the supply chain that are involved in the handling and processing of these substances.

    We are experiencing an increase in therapies that are focused on conditions affecting small patient populations, what we commonly refer to as orphan drugs. By U.S. definition, orphan drugs are those developed for treating conditions affecting fewer than 200,000 persons. According to the Evaluate Pharma, World Preview 2016, Outlook to 2022, from the period of September 2016 until 2022, sales volume in orphan drugs is expected to increase significantly, effectively doubling.

    Patients are requesting innovative drug-delivery systems that fit better with their mobile lifestyle of today as compared to several years ago. Having access to modern systems is important since it helps support patient acceptance and compliance. The digitalization of systems, for example, a pen system that reminds you to take your medication in a calculated dosage, supports this need and is likely to increase its importance within the (bio-)pharmaceutical industry.

    Meanwhile, major areas of the developed world are experiencing growth in aged populations which has resulted in an increase in associated diseases such as cancer and diabetes, to name but a few. Because illnesses like diabetes can often be treated in private settings, there has been an impact on the homecare sector, creating a need for appropriate devices to be used in this setting.

    Costs and their downward pressure on healthcare systems are also increasing. That means a greater need for efficient, but at the same time price-attractive treatments. Today, we see that in a lot of countries those drugs that have proven efficacy and therapeutic effect, and which offer advantages over existing therapies, are reimbursed. Pressures on pricing will also further support the homecare sector in an effort to avoid cost-intensive treatments in hospitals or at the local doctor.

    CP: What are the most important trends in aseptic fill/finish outsourcing today?
    PS:
    The primary trend we experience first-hand is the increase in demand of quality requirements from customers and regulatory bodies. To fulfill these requirements on a day-to-day base is a challenging task because the drug substances themselves have become ever more complex. Large molecules like biologics are, by their very nature, complex products. Their share in the overall global pharmaceutical market has increased continuously over the past several years. According to a 2016 IMS report, the global biologic medicines market is projected to exceed $390 billion by 2020, with sales rates growing anywhere from 10-15% annually.

    Another important trend is combination products which have increased in importance as (bio-)pharmaceutical companies look to more attractive drug-delivery devices to help differentiate their products. Such an approach creates both opportunities and challenges for contract development and manufacturing organizations (CDMOs). Starting with the opportunities, they result from a growing demand for higher-value filling requirements and the subsequent need to assemble and package the devices. The challenges arise from the non-standard nature of the devices and the fact that they are of course designed to appeal to the patient, but some of which with little regard for ability to manufacture. This situation easily results in complex, and therefore cost intensive, manual assembly operations.

    CP: How would you describe the current state of the aseptic fill/finish outsourcing market?
    PS:
    According to the business information portal Visiongain, over the past several years the global contract (bio-)pharmaceutical manufacturing market grew at an average annual rate of 7.5%. Therefore, we remain optimistic for the future and expect the global market to continue this growth in 2017.

    According to a 2016 survey by the trade magazine International Pharmaceutical Industry (IPI), which included more than 400 professionals from the (bio-)pharmaceutical and contract services industry, 73% answered ‘yes’ to the question that pertained to an increase in demand for outsourcing. The reasons given included a 41% response rate for a focus on core competencies, and 59% spread between their virtual character, such as a lack of in-house capabilities, or the use of suppliers to incorporate a secondary supply strategy. Approximately 80% of sponsor company respondents view contract relationships as partnerships. This too, is how we see and define our role in this business.

    Aging populations have created an increased demand for associated diseases like cancer, diabetes, autoimmune, metabolic, and nervous system disorders, as well as a demand for additional new diseases including orphan drug treatments.

    In our opinion, prefilled syringes are one of the growth drivers of the fill and finish market, and consequently for the outsourcing business, representing one of the most rapidly expanding segments of the injectable drug delivery device market. This is not surprising since they are able to offer key differentiating factors such as improved safety, accurate dosing, reduced risks of contamination, as well as ease of administration.

    When we look at the hurdles the industry will likely face, we can indeed expect new future challenges in various aspects such as in the regulatory, financing, human resources, or process field. That is why as an industry, we must work hard and smart, and in a well-orchestrated manner. This must be our priority if we are to meet the needs of the patients who are, afterall, at the very core of our reason for being. Members of this promising market need to overcome individual roadblocks successfully, which means achieving the required quality levels and the foresight to go in new and innovative directions in order to succeed. Doing this in the form of trustful partnerships will most likely increase ones chances for success in this industry.

    CP: What are the key new technology innovations making an impact?
    PS:
    We believe that technology must always be linked to, and aligned with the needs and demands of the market. With that said, we see major requirements for flexible and multi-product facilities.

    There is a trend for smaller batch sizes, resulting from therapies for a small population. This need must be reflected in the technological performance of the manufacturing companies as well as the respective service providers. This means finding appropriate ways to efficiently handle the smaller batch size itself, but also the higher switch rate from one order to the next. And, it means that next to the filling process itself, the decontamination of the cleanroom is affected. Innovative concepts in this field can help contribute to increased operational excellence in aseptic manufacturing. One of the two distinct cleanroom technologies available today is the restricted access barrier systems (RABS) technology, and the other being isolators. RABS achieves the sterility assurance level (SAL) required by regulatory authorities and allows for rapid product changeover along with high safety. To better meet future industry trends in quality, safety and flexibility, combining the advantages of isolator and RABS technology seems quite promising. Applying a form of “Improved RABS concept” and thus, achieving by today’s standards, a uniquely fast and fully-automated decontamination of the cleanroom using hydrogen peroxide (H2O2), means a high level of technological and process innovation.

    Single-use technology is another emerging trend along with innovation in the fill and finish segment. However, large parts of the industry do not believe that single-use equipment will replace stainless steel technology overall. Nevertheless, it can be a valuable option within special fields of the production process. Both technologies have their respective pros and cons. As a key guideline, single-use equipment is especially suitable in cases when a drug substance comes in direct contact with the equipment being used.

    CP: Where do you see the market down the road, say in five years time?
    PS:
    We see the increase in access to medicine in developing and emerging countries being one of the results of a continuous increase in globalization. This development generates new potential and growth opportunities for the market and its participants. In regards to supply chain and its requests from the customer end, its complexity is increased and becomes more multi-faceted. Applying digital innovations such as the successful collection, storing, analyzing and processing of what is called “Big Data”, can be helpful tools in supporting the production and supply planning processes for (bio-)pharmaceutical companies and their strategic partners.

    We see individual treatments increasing due to continuous advances in the discovery of the human body, and enabling subsequent targeted medical treatments.

    While outsourcing is on the rise, sponsor firms are becoming more selective about which service provider they are willing to partner with. CDMOs that consistently meet various global regulatory standards, quality requirements, and customer’s reliability expectations will clearly have a competitive advantage.

    The September 2016 PharmSource Information Services report revealed that the service provider market can be segmented into either “innovation-driven” CMOs, or “capacity-driven”. Innovation driven CMO’s, which supported a significant number of new drug application approvals over the past ten years, focus on higher-value market opportunities. Capacity-driven CMO’s are essentially focused on filling undifferentiated manufacturing capacity, and primarily produce generics and/or late lifecycle branded products.

    We also see the continuation in the consolidation of companies being part of the pharma and biotech medical market, along with an increase in investments and in modular manufacturing. 

    In conclusion, we believe the market will continue with promising opportunities for those companies that are well-orchestrated and prepared for the needs of their large and small (bio-)pharmaceutical customers today and tomorrow.

    CP: What is the latest news at Vetter on the aseptic fill/finish front?
    PS:
    In January, Vetter began operations in its expanded Visual Inspection and Logistics Center located in Ravensburg. The enlargement, in which we invested approximately €100 million ($107mn), bundles capacity for our final product inspection and logistics in one cutting-edge site. By finalizing the second construction stage of the site that was initially put into operation five years ago, we are now able to offer more than double the capacity for state-of-the-art quality control, cold-storage and room-temperature storage. Given the increasing industry-specific requirements emanating from the customer and regulatory side, we now provide even more efficient and flexible supply chain processes. The expanded center is located on approximately 50,000 square meters (538,000 square feet) of floor space and offers a 35,000-pallet warehouse capacity for storing pharmaceuticals in refrigeration or room temperature conditions. This allows us to react with greater flexibility to individual market and customer needs. 
    Related Searches
    • supply chain
    • singapore
    • Pharmaceutical manufacturing
    • Manufacturing
    Suggested For You
    Vetter continues its successful performance at the 2021 CMO Leadership Awards Vetter continues its successful performance at the 2021 CMO Leadership Awards
    Vetter continues to implement its long-term sustainability strategy Vetter continues to implement its long-term sustainability strategy
    Vetter Moves Into New HQ Vetter Moves Into New HQ
    Vetter continues its long-term investment strategy to sustain future growth Vetter continues its long-term investment strategy to sustain future growth
    Vetio Animal Health Vetio Animal Health
    Vetter, Microdermics Enter Strategic Drug Delivery Alliance Vetter, Microdermics Enter Strategic Drug Delivery Alliance
    So You Think You Know  All About Excipients? So You Think You Know All About Excipients?
    The Results Are In! The Results Are In!
    CROs & Next-Gen  Drug Development CROs & Next-Gen Drug Development
    Innovative Manufacturing Technology for Aseptic Filling Innovative Manufacturing Technology for Aseptic Filling
    Injectable Drug Delivery Trends Injectable Drug Delivery Trends
    Aseptic Manufacturing Trends Roundtable Aseptic Manufacturing Trends Roundtable
    Trump Picks New FDA Commish Trump Picks New FDA Commish
    Reality and Un-Reality:  Continuous Processing in Pharmaceutical Manufacturing Reality and Un-Reality: Continuous Processing in Pharmaceutical Manufacturing
    DCAT Week DCAT Week '17 Q&A: API Market Trends

    Related Features

    • Solid Dosage/Semi-solids
      Hygienic Packaging Technology

      Hygienic Packaging Technology

      Growing consumer demand for health products highlights hygienic packaging.
      John Brown, Vice President of Global Marketing, Selig 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21


    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Pharmaceutical Manufacturing  Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      Kristin Brooks, Managing Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Nutraceutical Manufacturing:  Meeting the Challenges of Today, Planning for  Tomorrow

      Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow

      Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • 2021 Contract  Manufacturing Survey

      2021 Contract Manufacturing Survey

      Our fourth annual audience poll indicates continued reliance on manufacturing partners, particularly for small businesses.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • APIs
      Small Molecule Development Trends

      Small Molecule Development Trends

      A Q&A with Cambrex Edinburgh’s site director, Mark Benger.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • APIs | Cytotoxics and High Potency Manufacturing
      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      A Q&A with Christian Dowdeswell, vice president and head of commercial development for small molecules at Lonza.
      Tim Wright, Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Development and manufacture of medicated chewing gum continues to gain momentum.
      Rukayat Adedeji, Contributing Writer 03.01.21

    • APIs
      Small Molecule API CDMO: A Capital Intensive Business?

      Small Molecule API CDMO: A Capital Intensive Business?

      Exploring small molecule API market trends.
      Dr. Michele Jermini and Dr. Enrico Polastro, Contributing Writers 03.01.21


    • Serialization
      Serialization: Level 5 Solution

      Serialization: Level 5 Solution

      Why a Level 5 solution is required for small pharma companies to fully harness serialization investment.
      Steve Wood, President & CEO, Covectra 03.01.21

    • Solid Dosage/Creams/Ointments
      High Drug Loading Amorphous Solid Dispersions

      High Drug Loading Amorphous Solid Dispersions

      A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings
      Deanna Mudie and Aaron Stewart, Lonza 01.27.21

    • Parenterals
      Parenteral Drug Delivery Trends

      Parenteral Drug Delivery Trends

      A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
      Kristin Brooks, Managing Editor, Contract Pharma 01.27.21

    Trending
    • Baxter Biopharma Solutions Enters Sterile Manufacturing Agreement For Novavax’ COVID-19 Vaccine
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • Pharmaron Acquires Biomanufacturing Site In The UK From AbbVie
    Breaking News
    • Jubilant Therapeutics Appoints Chief Scientific Officer
    • Iontas and Fair Journey Biologics Partner with Quell Therapeutics
    • Vetter Establishes Office in China
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Diets High In Fructose Could Cause Immune System Damage
    Nestlé Acquires Premium Water Brand Essentia
    Kaneka Probiotics Announces Launch of L. plantarum DR7
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President, COO
    Ashland Completes Expansion, Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcoVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs First OTC Home Molecular COVID-19 Test
    FDA Approves Second Sight's Argus 2s Retinal Prosthesis
    Cross Border Venture Financing Rose in Final Quarter of 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Sharp Appoints EU Qualified Person
    Baxter Biopharma Solutions Enters Sterile Manufacturing Agreement for Novavax’ COVID-19 Vaccine
    Metrics Contract Services Completes Russian Regulatory Inspection
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    It's International Women's Day—But What Does That Mean?
    e.l.f. Cosmetics and Chipotle Collaborate on Burrito-Inspired Makeup Collection
    Weekly Recap: Sephora Expansion, Ulta Partners with Loop, International Women’s Day & More
    Happi

    Latest Breaking News From Happi

    Cococare Appoints First Woman President
    Ross Highlights Triple Shaft Mixers
    Arm & Hammer Unveils Foot Wipes
    Ink World

    Latest Breaking News From Ink World

    Capital Printing Invests in 2nd Komori Press
    Arna Marketing Adds Canon’s ProStream, VarioPRINT iX Production Inkjet Presses
    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Xeikon details upcoming Xeikon Café TV seminars
    Resource Label Group acquires New England Label
    UV+EB-cured products rated 'easier to recycle'
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Arm & Hammer Launches Foot Wipes
    Kimberly-Clark Names Chief Research and Development Officer
    FPInnovations Develops Biodegradable Mask
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Australia Clears Conformis' iTotal PS Knee Replacement System
    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research
    Wearable Patch Market to Reach $27.8 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login